My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

0.6225 +0.0022 (+0.35%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2 3 4 5 6 Next >

35 Stocks Moving In Wednesday's Mid-Day Session ↗

December 08, 2021

Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 79% to $18.63. Insignia Systems recently announced the commencement of a formal process to explore strategic options...

Via Benzinga

Why Lexaria Shares Are Rising Today ↗

December 08, 2021

Lexaria Bioscience Corp (NASDAQ:LEXX) is trading higher We...

Via Benzinga

Read Why Lexaria Bioscience Shares Are Surging During Wednesday Premarket? ↗

December 08, 2021

Lexaria Bioscience Corp (NASDAQ: LEXX) has issued follow-up results from human clinical study HYPER-H21-2 of DehydraTECH-processed cannabidiol (CBD). The data...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 08, 2021

Gainers Lexaria Bioscience (NASDAQ:LEXX) shares increased by 30.28% to $6.41 during Wednesday's pre-market session. The company's market cap stands at $36.7...

Via Benzinga

Lexaria Bioscience Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD ↗

December 03, 2021

Lexaria Bioscience Corp. (NASDAQ:

Via Benzinga

Lexaria's DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study ↗

November 29, 2021

Lexaria Bioscience Corp

Via Benzinga

Lexaria Bioscience's DehydraTECH(TM) Drug Delivery Tech Finding Multiple Applications ↗

November 24, 2021

Lexaria intends to undertake its most ambitious study yet – HYPER-H21-4 – as it pursu...

Via Benzinga

Lexaria Bioscience Announces 2022 DehydraTECH(TM) R&D Programs ↗

November 18, 2021

Lexaria’s 2022 R&D programs are set to include research on hormone replacement, dementia, rheumatoid disease, and diabetes, among other conditions The program builds...

Via Benzinga

Lexaria Bioscience Corp. Embarks on Ambitious Hypertension Clinical Study ↗

November 15, 2021

Lexaria has embarked on its HYPER-H21-4 study, its fourth hypertension clinical study, and its most ambitious yet This study builds on the HYPER-H21-1 and HYPER-H21-2 findings,...

Via Benzinga

Lexaria Expands 2022 R&D Programs to Evaluate Alzheimer's, Diabetes ↗

November 11, 2021

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, today announced its plans for several new and ongoing DehydraTECH(TM)-applied R&D programs...

Via Benzinga

Lexaria Bioscience Corp. Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology's Efficacy in Reducing/Inhibiting Seizure Activity ↗

November 04, 2021

Lexaria recently announced the commencement of EPIL-A21-1, an animal study to evaluate whether DehydraTECH-CBD h...

Via Benzinga

Lexaria Bioscience Corp. to Expand Hypertension Clinical Program Through Most Ambitious Study to Date ↗

November 03, 2021

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, today announced a significant new study to expand its hypertension clinical program. In addition...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 03, 2021

Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion...

Via Benzinga

Lexaria Bioscience Corp. Begins R&D Program Comparing DehydraTECH-CBD with Generic CBD, Epidiolex ↗

November 02, 2021

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has begun a new study, EPIL-A21-1, designed to evaluate whether its DehydraTECH(TM)-CBD (“...

Via Benzinga

Lexaria Announces DehydraTECH-CBD Versus Prescription CBD Program In Treating Seizures ↗

November 01, 2021

Lexaria Bioscience Corp (NASDAQ: LEXX) has commenced a new study to compare the effectiveness of Epidiolex to DehydraTECH-cannabidiol (CBD) for reducing seizure...

Via Benzinga

Lexaria Bioscience Corp.'s DehydraTECH(TM) Addresses the Needs of Medical THC Users ↗

October 26, 2021

Lexaria’s THC absorption animal study yielded promising results on the patented DehydraTECH(TM) technology It showed that the technology required a shorter time to deliver...

Via Benzinga

Lexaria Starts IND-Enabling Program For DehydraTECH-CBD For Hypertension ↗

September 08, 2021

Lexaria Bioscience Corp (NASDAQ: LEXX) has formally begun the process towards an Investigational New Drug (IND) application filing with the FDA for its DehydraTECH...

Via Benzinga

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Results Of Human Clinical Study Showing Effective, Safe BP Reduction ↗

September 07, 2021

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study HYPER-H21-2, which features LEXX’s patented...

Via Benzinga

Why Lexaria Bioscience Shares Are Trading Higher Today ↗

September 07, 2021

Lexaria Bioscience Corp (NASDAQ: LEXX) is trading higher Tuesday after the company announced initial results from its human clinical study of DehydraTECH, saying the study...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 07, 2021

Gainers Pliant Therapeutics (NASDAQ:PLRX) shares rose 25.62% to $24.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $872.2...

Via Benzinga

Lexaria Bioscience's Formulated Cannabidiol Lowers Blood Pressure In Hypertension Patients ↗

September 07, 2021

Lexaria Bioscience Corp (NASDAQ: LEXX) has announced initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH-processed cannabidiol (CBD) for potential...

Via Benzinga

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targets Burgeoning Hypertension, Antiviral Therapeutics Markets With Drug Delivery Technology ↗

September 02, 2021

Lexaria has progressed significantly in evidencing that its patented DehydraTECH(TM) drug delivery technology can sufficiently improve the usable fraction of known antiviral...

Via Benzinga

Lexaria's R&D Program Reveals 5 Exciting Results Within 2 Months ↗

July 29, 2021

Image by Lucas Vasques on Unsplash Biotech company Lexaria Bioscience Corp. (NASDAQ: LEXX) has been making news for DehydraTECH™ — its proprietary disruptive and cost-...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 27, 2021

Gainers Eyegate Pharmaceuticals (NASDAQ:EYEG) shares increased by 131.41% to $7.22 during Tuesday's pre-market session. The company's market cap stands at $51.2...

Via Benzinga

38 Stocks Moving In Thursday's Mid-Day Session ↗

July 22, 2021

Gainers ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) shares climbed 129.7% to $12.75 after the company announced new results from its TATX-03 PolyTope Therapy, demonstrating...

Via Benzinga

61 Biggest Movers From Yesterday ↗

July 23, 2021

Gainers ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) shares jumped 138.2% to close at $13.22 on Thursday after the company announced new results from its TATX-03 PolyTope Therapy...

Via Benzinga

21 Stocks Moving in Thursday's Pre-Market Session ↗

July 22, 2021

Gainers PainReform Ltd (NASDAQ: PRFX) shares rose 123% to $7.00 in pre-market trading. Second Sight Medical Products Inc (NASDAQ: EYES) shares rose 29% to $5.57 in pre-market...

Via Benzinga

61 Biggest Movers From Yesterday ↗

July 22, 2021

Gainers Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares surged 159.2% to close at $5.34 on Wednesday after the company received a $28.3 million purchase order from Brazil's...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 21, 2021

Gainers Second Sight Medical (NASDAQ:EYES

Via Benzinga

Mid-Afternoon Market Update: Dow Jumps 250 Points; Sleep Number Shares Slide After Q2 Results ↗

July 21, 2021

Toward the end of trading Wednesday, the Dow traded up 0.73% to 34,765.42 while the NASDAQ rose 0.66% to 14,594.38. The S&P also rose, gaining 0.69% to 4,352.90. The U.S. has...

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.